Trial · NCT04414098
Ruxolitinib in the Treatment of Covid-19
NCT04414098, Phase 2, Unknown, Marcelo Iastrebner
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ruxolitinib in the Treatment of Covid-19. Trials, record NCT04414098. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04414098
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ruxolitinib in the Treatment of Covid-19
- NCT number
- NCT04414098
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Marcelo Iastrebner
- Conditions
- COVID-19
- Interventions
- INC424 / Ruxolitinib
- First posted
- 2020-06-04
- Last updated
- 2020-06-04
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate the efficacy of ruxolitinib in the treatment of COVID-19 severe acute respiratory syndrome | during 14 days after the commencement of treatment | Measuring the proportion of patients with clinical worsening (defined by a requirement of FIO2 \>50% and/or mechanical respiratory assistance) |
| Secondary | Evaluate the median duration of hospitalization. | after 45 days of commencement of treatment. | |
| Secondary | Evaluate the evolution of systemic inflammation parameters. | after 45 days of commencement of treatment. | Evaluation at the beginning (baseline), middle and end of the treatment with ruxolitinib of PCR, LDH, ESD, Ferritin and IL-6 (if available). |
| Secondary | Evaluate COVID-19 mortality rate | after 45 days of treatment. | |
| Secondary | Evaluate the proportion of the requirement of mechanical ventilation. | with a total follow-up of 45 days | |
| Secondary | Evaluate ruxolitinib adverse reactions | with a total follow-up of 45 days. | |
| Secondary | Evaluate the proportion of secondary infections during the treatment with ruxolitinib | after 45 days of commencement of treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04414098
GET https://conductscience.org/api/trials/v1/NCT04414098/registered